⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7561736 | 0.81 | — | — | |
| SCHEMBL28284591 | 0.79 | — | — | |
| SCHEMBL7797571 | 0.77 | GPR35 (0.30) | — | |
| SCHEMBL28317398 | 0.77 | — | — | |
| SCHEMBL28908630 | 0.73 | — | — | |
| SCHEMBL28701450 | 0.72 | — | — | |
| SCHEMBL17894915 | 0.72 | KDM4E (0.32) | — | |
| SCHEMBL2499734 | 0.70 | — | — | |
| SCHEMBL29286192 | 0.70 | POLB (0.33) | — | |
| SCHEMBL2512897 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12195447-B2 | Azolopyrimidine for the treatment of cancer-related disorders | ARCUS BIOSCIENCES, INC. (US) | 2025-01-14 | — | — | US | disclosed |
| CN-113015523-B | Solid forms of azopyrimidine compounds | 艾库斯生物科学有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-11993584-B2 | Solid forms of an azolopyrimidine compound | ARCUS BIOSCIENCES, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| EP-4310082-A2 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | Arcus Biosciences, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| US-20230338377-A1 | DOSING WITH AN AZOLOPYRIMIDINE COMPOUND | ARCUS BIOSCIENCES INC (US) | 2023-10-26 | — | — | US | disclosed |
| CN-116768859-A | Azolopyrimidines for the treatment of cancer related disorders | 艾库斯生物科学有限公司 | 2023-09-19 | — | — | CN | disclosed |
| EP-3570844-B1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES INC (US) | 2023-09-06 | — | — | EP | disclosed |
| EP-3618829-B1 | QUINAZOLINE-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES INC (US) | 2023-06-07 | — | — | EP | disclosed |
| CN-110214012-B | Azolopyrimidines for the treatment of cancer related disorders | 艾库斯生物科学有限公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-110612100-B | Quinazoline-pyridine derivatives for the treatment of diseases associated with cancer | 艾库斯生物科学有限公司 | 2023-04-14 | — | — | CN | disclosed |
| US-20130245044-A1 | TRIAZOLO[4, 5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2013-09-19 | — | — | US | disclosed |
| US-8450328-B2 | Triazolo[4,5-D]pyramidine derivatives and their use as purine receptor antagonists | VERNALIS (R&D) LIMITED (GB) | 2013-05-28 | — | — | US | disclosed |
| EP-2321321-B1 | TRIAZOLO [4, 5-D]PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS R&D LTD (GB) | 2012-02-08 | — | — | EP | disclosed |
| US-20110172252-A1 | TRIAZOLO[4,5-D]PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED | 2011-07-14 | — | — | US | disclosed |
| EP-2321321-A1 | TRIAZOLO [4, 5-D]PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | Vernalis (R&D) Limited (GB) | 2011-05-18 | — | — | EP | disclosed |
| WO-2009156737-A1 | TRIAZOLO [4, 5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS (R&D) LIMITED (GB) | 2009-12-30 | — | — | WO | disclosed |
| CN-1391577-A | Pharmaceutical compositions comprising metal complexes | ANORMED INC (CA) | 2003-01-15 | — | — | CN | disclosed |
| US-20020049190-A1 | Pharmaceutical compositions comprising metal complexes | ANORMED INC. (CA) | 2002-04-25 | — | — | US | disclosed |
| EP-1163247-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING METAL COMPLEXES | ANORMED INC. (CA) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000056743-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING METAL COMPLEXES | ANORMED INC. (CA) | 2000-09-28 | — | — | WO | disclosed |